Deep In “the Cave,” Eli Lilly’s CEO Decided Alzheimer’s Drug’s Fate

They called it “the cave.”

In an unmarked room in the middle of Eli Lilly & Co.’s Indianapolis campus, researchers holed up for months in 2012 poring over data from the company’s failed trials of its experimental Alzheimer’s disease treatment, solanezumab, looking for hidden signs the drug had worked.

Help employers find you! Check out all the jobs and post your resume.

MORE ON THIS TOPIC